A new trading day began on Monday, with Spyre Therapeutics Inc (NASDAQ: SYRE) stock price down -10.06% from the previous day of trading, before settling in for the closing price of $17.94. SYRE’s price has ranged from $16.71 to $40.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -49.91%. Meanwhile, its annual earnings per share averaged -8.65%. With a float of $51.14 million, this company’s outstanding shares have now reached $60.26 million.
The extent of productivity of a business whose workforce counts for 65 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Spyre Therapeutics Inc (SYRE) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 15.13%, while institutional ownership is 93.76%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.20% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Here are Spyre Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.66 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
The latest stats from [Spyre Therapeutics Inc, SYRE] show that its last 5-days average volume of 0.7 million was superior to 0.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.45%. Additionally, its Average True Range was 1.43.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 0.02%, which indicates a significant decrease from 0.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.10% in the past 14 days, which was higher than the 64.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.41, while its 200-day Moving Average is $26.13. Now, the first resistance to watch is $17.16. This is followed by the second major resistance level at $18.19. The third major resistance level sits at $18.71. If the price goes on to break the first support level at $15.62, it is likely to go to the next support level at $15.10. Assuming the price breaks the second support level, the third support level stands at $14.07.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
With a market capitalization of 972.25 million, the company has a total of 60,257K Shares Outstanding. Currently, annual sales are 0 K while annual income is -208,020 K. The company’s previous quarter sales were 0 K while its latest quarter income was -56,300 K.
